GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (WBO:MYL) » Definitions » Cyclically Adjusted PB Ratio

Viatris (WBO:MYL) Cyclically Adjusted PB Ratio : 0.52 (As of Apr. 28, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Viatris Cyclically Adjusted PB Ratio?

As of today (2024-04-28), Viatris's current share price is €10.835. Viatris's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was €20.86. Viatris's Cyclically Adjusted PB Ratio for today is 0.52.

The historical rank and industry rank for Viatris's Cyclically Adjusted PB Ratio or its related term are showing as below:

WBO:MYL' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.38   Med: 2.28   Max: 8.54
Current: 0.5

During the past years, Viatris's highest Cyclically Adjusted PB Ratio was 8.54. The lowest was 0.38. And the median was 2.28.

WBO:MYL's Cyclically Adjusted PB Ratio is ranked better than
85.78% of 647 companies
in the Drug Manufacturers industry
Industry Median: 1.75 vs WBO:MYL: 0.50

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Viatris's adjusted book value per share data for the three months ended in Dec. 2023 was €15.631. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €20.86 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Viatris Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Viatris's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris Cyclically Adjusted PB Ratio Chart

Viatris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.22 1.05 0.69 0.52 0.47

Viatris Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.43 0.44 0.43 0.47

Competitive Comparison of Viatris's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viatris's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Viatris's Cyclically Adjusted PB Ratio falls into.



Viatris Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Viatris's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=10.835/20.86
=0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viatris's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Viatris's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=15.631/129.4194*129.4194
=15.631

Current CPI (Dec. 2023) = 129.4194.

Viatris Quarterly Data

Book Value per Share CPI Adj_Book
201403 6.145 99.695 7.977
201406 6.562 100.560 8.445
201409 7.026 100.428 9.054
201412 7.037 99.070 9.193
201503 17.127 99.621 22.250
201506 17.343 100.684 22.293
201509 17.782 100.392 22.924
201512 18.270 99.792 23.694
201603 18.775 100.470 24.185
201606 18.083 101.688 23.014
201609 19.695 101.861 25.023
201612 19.685 101.863 25.010
201703 20.336 102.862 25.586
201706 21.304 103.349 26.678
201709 20.792 104.136 25.840
201712 21.451 104.011 26.691
201803 20.735 105.290 25.487
201806 20.272 106.317 24.677
201809 20.055 106.507 24.369
201812 20.735 105.998 25.317
201903 20.378 107.251 24.590
201906 20.420 108.070 24.454
201909 20.167 108.329 24.093
201912 20.722 108.420 24.736
202003 19.717 108.902 23.432
202006 20.177 108.767 24.008
202009 20.608 109.815 24.287
202012 15.634 109.897 18.411
202103 14.884 111.754 17.237
202106 14.556 114.631 16.434
202109 14.859 115.734 16.616
202112 14.995 117.630 16.498
202203 15.315 121.301 16.340
202206 15.453 125.017 15.997
202209 15.977 125.227 16.512
202212 16.389 125.222 16.938
202303 16.019 127.348 16.280
202306 16.043 128.729 16.129
202309 16.297 129.860 16.242
202312 15.631 129.419 15.631

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Viatris  (WBO:MYL) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Viatris Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Viatris's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Viatris (WBO:MYL) Business Description

Industry
Traded in Other Exchanges
Address
1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Viatris (WBO:MYL) Headlines

No Headlines